Patents by Inventor Bruce Allan Hay
Bruce Allan Hay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10450345Abstract: A method for purification of a target in a solution includes providing a target in a solution, the solution comprising one or more contaminants, providing a polymer conjugate in the solution, wherein the polymer conjugate is configured to specifically bind the target, incubating the solution at a first temperature to facilitate binding of the polymer conjugate to the target, providing an environmentally-responsive block copolymer in the solution, wherein the environmentally-responsive block copolymer comprises one or more of an ethylene oxide (EO), a propylene oxide (PO), or an EO/PO block copolymer, and heating the solution comprising the environmentally-responsive block copolymer and the polymer conjugate bound to the target at a second temperature to initiate a liquid-liquid phase separation, wherein the liquid-liquid phase separation produces an aqueous phase and a liquid polymer phase, and wherein the liquid polymer phase comprises the polymer conjugate bound to the target.Type: GrantFiled: June 9, 2017Date of Patent: October 22, 2019Assignee: General Electric CompanyInventors: Erik Leeming Kvam, Bruce Allan Hay, Ernest William Kovacs
-
Publication number: 20180354987Abstract: A method for purification of a target in a solution includes providing a target in a solution, the solution comprising one or more contaminants, providing a polymer conjugate in the solution, wherein the polymer conjugate is configured to specifically bind the target, incubating the solution at a first temperature to facilitate binding of the polymer conjugate to the target, providing an environmentally-responsive block copolymer in the solution, wherein the environmentally-responsive block copolymer comprises one or more of an ethylene oxide (EO), a propylene oxide (PO), or an EO/PO block copolymer, and heating the solution comprising the environmentally-responsive block copolymer and the polymer conjugate bound to the target at a second temperature to initiate a liquid-liquid phase separation, wherein the liquid-liquid phase separation produces an aqueous phase and a liquid polymer phase, and wherein the liquid polymer phase comprises the polymer conjugate bound to the target.Type: ApplicationFiled: June 9, 2017Publication date: December 13, 2018Inventors: Erik Leeming Kvam, Bruce Allan Hay, Ernest William Kovacs
-
Patent number: 9846206Abstract: Magnetic material imaging (MMI) system including first and second sets of field-generating coils. Each of the field-generating coils of the first and second sets has an elongated segment that extends along an imaging axis of the medical imaging system. The imaging axis extends through a region-of-interest (ROI) of an object. The elongated segments of the first set of field-generating coils are positioned opposite the elongated segments of the second set of field-generating coils and the ROI is located between the first and second sets of field-generating coils. The MMI system also includes a coil-control module configured to control a flow of current through the first and second sets of field-generating coils to generate a selection field and to generate a drive field. The selection and drive fields combine to form a movable 1D field free region (FFR) that extends through the ROI.Type: GrantFiled: August 19, 2013Date of Patent: December 19, 2017Assignee: General Electric CompanyInventors: Dominic Michael Graziani, Thomas Kwok-Fah Foo, Luca Marinelli, Daniel Eugene Meyer, Bruce Allan Hay
-
Patent number: 9827335Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: GrantFiled: October 21, 2015Date of Patent: November 28, 2017Assignee: General Electric CompanyInventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Patent number: 9474810Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.Type: GrantFiled: March 2, 2012Date of Patent: October 25, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Daniel Eugene Meyer, Brian Christopher Bales, Michael Todd Luttrell
-
Patent number: 9468693Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: GrantFiled: January 23, 2014Date of Patent: October 18, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Jack Mathew Webster
-
Patent number: 9468692Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: GrantFiled: January 23, 2014Date of Patent: October 18, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Jack Mathew Webster
-
Patent number: 9399075Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.Type: GrantFiled: April 29, 2013Date of Patent: July 26, 2016Assignee: General Electric CompanyInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino, Bruce Allan Hay, Amit Mohan Kulkarni
-
Publication number: 20160038617Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: ApplicationFiled: October 21, 2015Publication date: February 11, 2016Inventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Patent number: 9251937Abstract: A method of sterilizing a nanoparticle preparation at a high temperature is provided. A plurality of nanoparticles are purified to form the preparation, wherein the nanoparticles comprise at least a core and a shell and the shell comprises one or more ligand species attached to the core. The nanoparticle preparation is made by a purified nanoparticle composition, a carrier fluid and an excess of the one or more ligand species not attached to the core. The ligand species attached to the core and the excess ligand species added after purification are structurally identical. The nanoparticle preparation provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.Type: GrantFiled: June 29, 2012Date of Patent: February 2, 2016Assignee: General Electric CompanyInventors: Brian Christopher Bales, Brian James Grimmond, Daniel Eugene Meyer, Bruce Allan Hay, Michael Todd Luttrell
-
Patent number: 9205155Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: GrantFiled: October 30, 2009Date of Patent: December 8, 2015Assignee: General Electric CompanyInventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Publication number: 20150285720Abstract: Disclosed are novel cold fixation methods and reagents comprising contacting a biological sample with a reagent for fixation at a temperature of less than 20° C. where the reagent comprises an aqueous buffer, a water soluble alkylnitrile, C2 to C6 alkyl ester, or combination thereof, and formaldehyde to the aqueous buffer solution and removing the biological sample from contact with the reagent.Type: ApplicationFiled: April 8, 2014Publication date: October 8, 2015Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan Hay, Brian James Grimmond, Lisa Anne Lowery, Qing Li, Patrick McCoy Spooner, Christine Angela Morton
-
Publication number: 20150202333Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: ApplicationFiled: January 23, 2014Publication date: July 23, 2015Applicant: General Electric CompanyInventors: Bruce Allan Hay, Jack Mathew Webster
-
Publication number: 20150202332Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: ApplicationFiled: January 23, 2014Publication date: July 23, 2015Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan Hay, Jack Mathew Webster
-
Patent number: 8895068Abstract: A nanoparticle composition is provided, wherein the composition comprises a nanoparticulate metal oxide; and a phosphorylated polyol comprising at least two phosphate groups. The polyol comprises one or more hydrophilic groups selected from the group consisting of polyethylene ether moieties, polypropylene ether moieties, polybutylene ether moieties, and combinations of two or more of the foregoing hydrophilic moieties. A method of making the nanoparticle composition is also provided. The nanoparticle compositions provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.Type: GrantFiled: December 15, 2010Date of Patent: November 25, 2014Assignee: General Electric CompanyInventors: Bruce Allan Hay, Brian Christopher Bales, Michael Todd Luttrell, Binil Itty Ipe Kandapallil
-
Patent number: 8889103Abstract: A diagnostic agent composition is provided which comprises a nanoparticle composition and a pharmaceutically acceptable carrier or excipient. The nanoparticle composition comprises a nanoparticulate metal oxide and a phosphorylated polyol, wherein the phosphorylated polyol comprises at least two phosphate groups and one or more hydrophilic groups selected from the group consisting of polyethylene ether moieties, polypropylene ether moieties, polybutylene ether moieties, and combinations of two or more of the foregoing hydrophilic moieties. The disclosure provides detailed guidance on methods of making and using such diagnostic agent compositions. The diagnostic agent compositions provided by the present invention are useful as contrast agents for medical diagnostic imaging techniques such as magnetic resonance (MR) imaging and X-ray imaging. The diagnostic agent composition may be administered to a subject via a variety of techniques, among them injection, inhalation, and ingestion.Type: GrantFiled: December 15, 2010Date of Patent: November 18, 2014Assignee: General Electric CompanyInventors: Bruce Allan Hay, Brian Christopher Bales, Michael Todd Luttrell, Binil Itty Ipe Kandapallil
-
Patent number: 8728529Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: GrantFiled: December 29, 2008Date of Patent: May 20, 2014Assignee: General Electric CompanyInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
-
Publication number: 20140003997Abstract: A method of sterilizing a nanoparticle preparation at a high temperature is provided. A plurality of nanoparticles are purified to form the preparation, wherein the nanoparticles comprise at least a core and a shell and the shell comprises one or more ligand species attached to the core. The nanoparticle preparation is made by a purified nanoparticle composition, a carrier fluid and an excess of the one or more ligand species not attached to the core. The ligand species attached to the core and the excess ligand species added after purification are structurally identical. The nanoparticle preparation provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.Type: ApplicationFiled: June 29, 2012Publication date: January 2, 2014Applicant: GENERAL ELECTRIC COMPANYInventors: Brian Christopher Bales, Brian James Grimmond, Daniel Eugene Meyer, Bruce Allan Hay, Michael Todd Luttrell
-
Patent number: 8574549Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: GrantFiled: December 29, 2008Date of Patent: November 5, 2013Assignee: General Electric CompanyInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michacl Ernest Marino
-
Publication number: 20130230463Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.Type: ApplicationFiled: March 2, 2012Publication date: September 5, 2013Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan HAY, Daniel Eugene MEYER, Brian Christopher BALES, Michael Todd LUTTRELL